CTOs on the Move


 
Medterra takes pride in providing our customers with the highest quality pure CBD, grown and processed in the USA.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

AVANZA Laboratories

AVANZA Laboratories is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ScriptPro LLC

ScriptPro LLC is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Mission, KS. To find more information about ScriptPro LLC, please visit www.scriptpro.com

NARBHA

Northern Arizona Regional Behavioral Health Authority (NARBHA) was founded in 1967.  It is a private, not-for-profit managed care corporation designated by the Arizona Department of Health Services as being responsible for the planning, implementation, funding, monitoring and administration of publicly funded comprehensive behavioral health services in Northern Arizona. NARBHA serves over 700,000 people throughout 62,000 square miles (or ½ of the state) of northern Arizona, including the Hopi Reservation. NARBHA subcontracts with ten Responsible Agencies (RAs), over 70 additional behavioral health providers, and operated under Memorandums of Understanding (MOU) with ten Native American tribes, offering choice of services to members throughout northern Arizona. NARBHA contracts with NAZCARE, Recovery Innovations of Arizona (RIAZ), and MIKID to offer peer and family support programs and services. Consumer/ family involvement is included on eight standing NARBHA and numerous ad hoc NARBHA Committees and Workgroups.

Rosewood Village

Rosewood Village is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T3D Therapeutics

T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.